Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 13:13:79-82.
doi: 10.2147/BTT.S195512. eCollection 2019.

Dupilumab side effect in a patient with atopic dermatitis: a case report study

Sakhar S Albader  1 , Abdulmajeed A Alharbi  2 , Rakan F Alenezi  1 , Fahad M Alsaif  3
Affiliations

Dupilumab side effect in a patient with atopic dermatitis: a case report study

Sakhar S Albader et al. Biologics. .

Abstract

Atopic dermatitis (eczema) is a common chronic disease that is described as severe itching associated with recurrent eczematous lesions. In 2017 the US Food and Drug Administration approved dupilumab for treatment of adults with moderate to severe atopic dermatitis not well controlled with topical therapies or when other therapies are inadvisable. Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and IL-13 signaling by specifically binding to the IL-4R-alpha subunit shared by the IL-4 and IL-13 receptor complexes. There are many adverse effects reported after dupilumab therapy; commonly reported adverse effects include local injection site reactions, conjunctivitis, headache, and nasopharyngitis. Some adverse effects are rare, eg, alopecia areata and cicatricial extropion. We report a new case of a 28-year-old female who experienced face and neck rash after dupilumab injection.

Keywords: atopic dermatitis; dupilumab, eczema, adverse effect.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Erythematous slightly edematous patch over the cheek (A) and chin (B).
Figure 2
Figure 2
Multiple erythematous patches over the neck without scales.
See this image and copyright information in PMC

References

    1. Eshtiaghi P, Gooderham MJ. Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. Core Evid. 2018;13:13. doi:10.2147/CE.S133661 - DOI - PMC - PubMed
    1. Simpson EL. Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials. Dermatol Ther. 2017;7(2):243–248. doi:10.1007/s13555-017-0181-6 - DOI - PMC - PubMed
    1. Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep. 2018;4(2):143–144. doi:10.1016/j.jdcr.2017.11.020 - DOI - PMC - PubMed
    1. Penzi LR, Yasuda M, Manatis-Lornell A, Hagigeorges D, Senna MM. Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab. JAMA Dermatol. 2018;154(11). doi:10.1001/jamadermatol.2018.2976 - DOI - PubMed
    1. Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. Allergy Asthma Immunol Res. 2016;8(3):181–190. doi:10.4168/aair.2016.8.3.18 - DOI - PMC - PubMed

LinkOut - more resources